Trials / Withdrawn
WithdrawnNCT02258880
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
A Phase 2, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SUN13837 Administered 28 Doses (27/28 Days) to Adult Subjects With an Acute Ischemic Stroke
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of SUN13837 and to determine whether SUN13837 improves the physical performance, relative to placebo, following an acute stroke in adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SUN13837 | |
| DRUG | placebo |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2016-05-01
- Completion
- 2016-05-01
- First posted
- 2014-10-08
- Last updated
- 2015-10-20
Locations
53 sites across 4 countries: United States, Canada, Israel, South Africa
Source: ClinicalTrials.gov record NCT02258880. Inclusion in this directory is not an endorsement.